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Background: Lung cancer is the second most diagnosed cancer and 
the leading cause of cancer-related mortality in Canada. Surgical resec-
tion is the treatment of choice for patients with stage I non–small-cell 
lung cancer (NSCLC). However, 20% to 30% of them are deemed 
medically inoperable and may be offered radiation therapy. Standard 
external-beam radiation therapy (EBRT) is associated with high rates 
of local recurrence and poor long-term survival. Stereotactic ablative 
radiation therapy (SABR) is increasingly being proposed for inop-
erable patients, and the use of this treatment modality for operable 
patients is also being contemplated. The objective of this guideline is 
to review the efficacy and safety of SABR in these two clinical situa-
tions and to develop evidence-based recommendations.
Method: A review of the scientific literature published up to December 
2013 was performed. A total of 44 publications were included.
Recommendations: Considering the evidence available to date, the 
Comité de l’évolution des pratiques en oncologie recommends the 
following: (1) for medically operable patients with stage T1-2N0M0 
NSCLC, surgery remains the standard treatment because comparative 
data regarding the efficacy of SABR and surgery are currently insufficient 
for SABR to be considered an equivalent alternative to surgery for these 
patients; (2) for medically inoperable patients with stage T1-2N0M0 
NSCLC or medically operable patients who refuse surgery, SABR 
should be preferred to standard EBRT (grade B recommendation); (3) 
the biological equivalent dose (BED
10
) used for SABR treatment should 
be at least 100 Gy (grade B recommendation); (4) for patients with a 
central tumor, a large-volume tumor (large planning target volume) or 
severe pulmonary comorbidity, a risk-adapted schedule should be used 
(dose reduction or increase in the number of fractions; grade B recom-
mendation); (5) the choice of using SABR to treat NSCLC should be 
discussed within tumor boards; treatment with SABR (or with standard 
EBRT) should not be considered for patients whose life expectancy is 
very limited because of comorbidities (grade D recommendation).
Key Words: Stereotactic ablative radiation therapy, Non-small-cell 
lung cancer, Inoperable patients, Operable patients.
(J Thorac Oncol. 2015;10: 872–882)
Lung cancer is the second most diagnosed cancer and the leading cause of cancer death in Canada. Long-term sur-
vival in these patients is poor, the overall 5-year survival 
rate being 15%.1 Of patients newly diagnosed with non–
small-cell lung cancer (NSCLC), 15% to 20% are found to 
have stage I disease.2,3 Surgical resection is the treatment of 
choice for these patients. However, approximately 20% to 
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30% of them are deemed inoperable because of comorbidi-
ties.4,5 These patients are usually offered radiation therapy. 
when this treatment is delivered with standard external-beam 
radiation therapy (EBRT) techniques, local 3-year recurrence 
rates are as high as 29% to 57%, and overall survival rates are 
as low as 20% to 50% (Supplemental Table 1, Supplemental 
Digital Content, http://links.lww.com/JTO/A820).
Stereotactic ablative radiation therapy (SABR) is an 
alternative EBRT technique that uses very high doses of radia-
tion delivered with very high precision. Until recently, studies 
evaluating the efficacy and safety of SABR for the treatment 
of early-stage NSCLC have mainly focused on medically 
inoperable patients. The good local control data observed 
with SABR have led to consideration that SABR might be an 
alternative to surgery for operable patients with early-stage 
NSCLC (T1-2N0). The objective of this clinical guideline is 
to evaluate the efficacy and safety of SABR for the treatment 
of NSCLC in these two clinical situations.
METHODS
A review of the scientific literature published up to 
December 2013 was performed in PubMed with the following 
keywords: radiosurgery (MeSH), stereotactic body radiother-
apy, stereotactic body radiation therapy, stereotactic radio-
therapy, stereotactic ablative radiotherapy, lung neoplasms 
(MeSH), lung cancer, lung neoplasia, and non–small-cell lung 
cancer. Studies evaluating the efficacy and safety of SABR for 
the treatment of NSCLC in inoperable and operable patients 
were considered for inclusion, as well as studies comparing 
SABR with standard EBRT or surgery. For the treatment of 
inoperable patients, only prospective studies were included, 
and for the treatment of operable patients, both prospective and 
retrospective studies were selected. Studies evaluating the use 
of SABR for the delivery of a boost dose in the treatment of 
patients with N+ stage disease or the treatment of lung metas-
tases were excluded. Economic studies were also excluded. 
Abstracts from international conferences were considered if 
they reported randomized controlled trial (RCT) results.
The levels of evidence and grades of recommendations 
were rated using the American Society of Clinical Oncology 
and European Society for Medical Oncology grading system.6 
The original guideline was developed by a subcommittee of 
the Comité de l’évolution des pratiques en oncologie (CEPO), 
reviewed by independent external experts, and, lastly, adopted 
by the CEPO by consensus. This article presents the highlights 
of an original clinical guideline, which is available in French 
at www.inesss.qc.ca.
RESULTS
The literature review included 44 articles. No RCTs 
were found. The main efficacy end points were local control, 
overall survival, and cancer-specific survival.
SABR in Inoperable Patients
Twenty one-arm phase I/II or II prospective studies have 
evaluated the efficacy of SABR for the treatment of NSCLC 
in inoperable patients.7–29 Two of these evaluated the impact 
of SABR on quality of life.7,12 Most of the studies included 
less than 70 patients. Operable patients who refused surgery 
accounted for more than 10% of the total cohort in eight of 
the 20 studies. The distribution of patients with stage T1 and 
T2 disease was relatively uniform across the studies, with a 
median of approximately 65% of patients with T1 stage and 
35% with T2 stage. Five studies included patients whose 
lesion was not histologically confirmed as NSCLC (8–36% of 
the cohorts).7,9,11,16,19,20
The results for local control, overall survival, and cancer-
specific survival are presented in Tables 1 and 2. The 3-year 
local control rates varied from 80% to 97.6%, except in one 
study (67.9%).23 At 3 years, cancer-specific survival varied 
from 72.5% to 88% and overall survival varied from 37.4% 
to 71.7%. Typically, 40% to 70% of the deaths were related 
to a cause other than cancer. The overall survival results were 
similar for central and peripheral tumors.11,18
Overall, the toxicity profile was favorable. Grades 1 
and 2 toxicities were very frequent, the most common being 
pneumonitis (up to 87%), fatigue (up to 50%), pleural effu-
sion (up to 18%), rib fracture (up to 15%), and dermatitis (up 
to 10%). Grade 3 or higher toxicity rates were generally of 
5% or less. Five studies reported higher rates of severe tox-
icities than what has been observed overall (15.7–26.7%), 
such as pneumonitis,10 other respiratory toxicities,10,13,18,20,24 
and nonpulmonary toxicities (pain and a deterioration in 
performance status).24 In the other 15 studies, the most 
common grade 3 or higher toxicities were pneumonitis (up 
to 6.4%), thoracic pain (up to 4.6%), and dyspnea (up to 
1.9%). The prognostic factors associated with severe tox-
icities were large planning target volume (PTV, ≥65 ml),10 
large gross target volume (>10 ml)17 and central tumor loca-
tion.17 Only one study18 reported treatment-related deaths, 
from pneumonia (n = 3 of 70), hemoptysis (n = 1), and 
respiratory failure (n = 1).
The data on changes in respiratory function were het-
erogeneous. The following results were observed: no change,7 
reduced forced expiratory volume in 1 second (−15.5%),7 
reduced diffusing capacity of carbon monoxide (−11% and 
−16.7%),7,14 and reduced forced vital capacity in patients with 
cardiovascular diseases (−30.5%).19 Fakiris et al.18 reported 
that of the 47 patients who were not oxygen-dependent before 
treatment, 13 (27.7%) became so at a median time of 55.6 
months. In a recent update of the 2010 Timmerman et al.13 
study, mean percent predicted forced expiratory volume in 1 
second and diffusing capacity of carbon monoxide declines 
2 years after the treatment were 5.8% and 6.3% respectively, 
and not significantly different.30 SABR did not change quality 
of life at 1 year,7,12 except for an improvement in emotional 
functioning.12
Comparison of SABR and Standard 
EBRT in Inoperable Patients
Three retrospective studies31–33 and one meta-analysis 
of observational studies34 compared SABR with standard 
EBRT. In the retrospective studies, the standard EBRT doses 
used were high (70–80 Gy)31,33 or variable.32 Shirvani et al.32 
used propensity-score matching. A summary of the results is 
presented in Table 3. SABR was associated with a significant 
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TABLE 1.  Summary of Prospective Studies Evaluating SABR in Medically Inoperable NSCLC Patients (Level III Evidence)
Study  
(Median  
Follow-up) n
Operable 
Patientsa
No Histologic  
Confirmation 
(%)
T Stage  
Distribution
SABR Dose/ 
fx/Isodoseb
Local  
Control
Overall  
Survival
Cancer- 
Specific  
Survival
Videtic et al.7  
(17.6 months)
21 5% 24 T1: 71%,  
T2: 29%
Based on tumor location:  
P: 60 Gy/3 fx/81–90%;  
C: 50 Gy/5 fx/97–100%
1-year: 100% 1-year: 86% NA
Shibamoto et al.8 
(36 months)
180 33% 0 T1: 71%, 
T2: 29%  
(≤ 5 cm)
Based on tumor size:  
44–52 Gy/4 fx/ 
isocenter
3-year: 83%;
3-yearc: 81%
3-year: 69%; 
5-year: 52%; 
3-yearc: 59%
3-yearc: 82%
Taremi et al.9  
(19.1 months)
108 Not eligible 24 T1: 80%,  
T2: 20%
Based on tumor location:  
P: 48–60 Gy/3–4 fx/95% 
of PTV; C: 50–60 Gy/ 
8–10 fx/95% of PTV
1-year: 92%; 
4-year: 89%
1-year: 84%; 
4-year: 30%
1-year: 92%; 
4-year: 77%
Bral et al.10  
(16 monthsd)
40 Eligible but 
NA
0 T1: 65%,  
T2: 35%  
(≤ 6 cm)
Based on tumor location:  
P: 60 Gy/3 fx/90%  
of PTV; C: 60 Gy/4 fx/ 
90% of PTV
1-year: 97%; 
2-year: 84%
2-year: 52% NA
Baba et al.11  
(26 monthsd)
124 32% 8 T1: 70%,  
T2: 30%
Based on tumor size: 
44–52 Gy/4 fx/isocenter
3-year: 80% 3-year: 71% 3-year: 87%
van der Voort van 
Zyp et al.12  
(17 months)
39 15% 0 T1: 44%,  
T2: 54%,  
T3: 3%
Based on tumor location:  
P: 60 Gy/3 fx/78–87%;  
C: 48–50 Gy/5–6 fx/ 
78–87%
1-year: 97%; 
2-year: 97%
1-year: 75%; 
2-year: 62%
NA
Timmerman et al.13 
(34.4 months)
55 Not eligible 0 T1: 80%,  
T2: 20%
60 Gy/3 fx/95% of PTV 3-year: 97.6% Med: 41.1 months; 
3-year: 55.78%
NA
Collins et al.14  
(25 monthsd)
20 Not eligible 0 NA (<4 cm  
or <30 ml)
Based on the presence  
of adjacent critical  
structure: 42–60 Gy/ 
3 fx/95% of PTV
At analysis:  
100%
2-year: 87% NA
Vahdat et al.15  
(43 monthsd)
2-year: 95% 2-year: 90%
Ricardi et al.16  
(28 months)
62 10% 35.5 T1: 69%,  
T2: 31%  
(≤ 5 cm)
45 Gy/3 fx/80% 2-year: 92.7%; 
3-year: 87.8%
2-year: 69.2%; 
3-year: 57.1%
2-year: 79.4%; 
3-year: 72.5%
Timmerman et al.17 
(17.5 months)
70 Not eligible 0 T1: 49%,  
T2: 51%  
(≤ 7 cm)
Based on tumor stage:  
T1: 60 Gy/3 fx/80%;  
T2: 66 Gy/3 fx/80%
2-year: 95% Med: 32.6 months; 
2-year: 55%
NA
Fakiris et al.18  
(50 months)
3-year: 88.1% Med: 32.4 months; 
3-year: 42.7%
3-year: 81.7%
Baumann et al.19  
(23 months)
57 7% 33 T1: 70%,  
T2: 30%
45 Gy/3 fx/67% At analysis: 96% At analysis: 65% NA
Baumann et al.20  
(35 months)
3-year: 92% Med: 40.6 months; 
1-year: 86%; 
2-year: 65%; 
3-year: 60%
1-year: 93%; 
2-year: 88%; 
3-year: 88%
Koto et al.21  
(32 months)
31 35% 0 T1: 61%,  
T2: 39%  
(≤ 5 cm)
Based on the presence  
of adjacent critical  
structure: 60 or 45 Gy/ 
8 or 3 fx/isocenter
3-year, T1/T2: 
77.9%/40%
3-year: 71.7% 3-year: 83.5%
Scorsetti et al.22  
(14 months)
43 Not eligible 2 T1: 67%,  
T2: 33%
32 Gy/4 fx/NA NA 1-year: 93%; 
2-year: 53%
NA
Hof et al.64  
(15 months)
42 Not eligible 0 T1: 40%,  
T2: 50%,  
T3: 10%
19–30 Gy/1 fx/isocenter 1-year: 89.5%; 
2-year: 67.9%; 
3-year: 67.9%
1-year: 74.5%; 
2-year: 65.4%; 
3-year: 37.4%
NA
Hoyer et al.24  
(2.4 years)
40 Not eligible 2.5 T1: 55%;  
T2: 45%  
(<6 cm)
45 Gy/3 fx/isocenter 2-year: 85% 2-year: 48% 2-year: 62%
Zimmermann et 
al.25 (17 months)
68 Not eligible 0 NA Initial protocol: 24 Gy/4  
fx to 30 Gy/3 fx;  
Based on tumor  
location: P: 37.5 Gy/ 
3 fx/60%; C: 35 Gy/ 
5 fx/60%
1-year: 96%; 
2-year: 88%; 
3-year: 88%
1-year: 83%; 
2-year: 71%; 
3-year: 51%
1-year: 96%; 
2-year: 82%; 
3-year: 73%
(Continued)
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overall survival benefit in all the retrospective studies. The 
cancer-specific survival results were not significantly differ-
ent between groups, and the local control data were not con-
sistent between the studies, showing no difference31 or an 
advantage for SABR.33 The meta-analysis showed that overall 
survival and cancer-specific survival were significantly lon-
ger in patients treated with SABR. The rates of grade 3 or 
higher toxicities were low with both approaches (all ≤2%), 
although they were slightly higher with SABR than with stan-
dard EBRT.34
Studies that have evaluated standard EBRT for the 
treatment of NSCLC in similar patients were also examined 
to better assess the two approaches (Supplemental Table 1, 
Supplemental Digital Content, http://links.lww.com/JTO/
A820). It was noted that the stage distribution was slightly 
different in the studies of standard EBRT than in those of 
SABR (T1: 53% vs. 65%; T2: 47% vs. 35%). Moreover, 
about one-third of the EBRT studies were published before 
2000.35–39 The medians for the reported local control, overall 
survival, and cancer-specific survival rates were calculated 
without any weighting procedures (Table 4). At 3 years, the 
median values were higher with SABR than with standard 
EBRT for local control (relative increase of 73%), overall 
survival (73%), and cancer-specific survival (55%).
SABR for Operable Patients
Two prospective8,28 and seven retrospective40–46 observa-
tional studies evaluated the efficacy and safety of SABR in 
operable patients. In seven of these studies, operable patients 
had refused surgery, and they constituted a subgroup of patients 
in a larger cohort consisting predominantly of inoperable pat
ients.8,28,41,42,44–46 The results are summarized in Table 5. The 
local control and cancer-specific survival data were in similar 
ranges to those for inoperable patients. As expected, overall 
survival was better in the operable patients. Toxicities were 
reported specifically for operable patients in only two stud-
ies.40,43 The grade 3 toxicity rates in these two studies were 2% 
and 9.2%. No treatment-related deaths were reported.
Yoon et al.26  
(13 months)
21 24% 0 T1: 62%,  
T2: 38%
Initial protocol: 
30 Gy/3 fx/NA; 
Safety confirmed: 
40 Gy/4 fx increased to 
48 Gy/4 fx/NA
1-year: 93%; 
2-year: 81%
1-year: 89%;  
2-year: 51%
NA
Nagata et al.27 
(22–30 months, 
depending on 
disease stage)
45 40% 0 T1: 71%,  
T2: 29%  
(<4 cm)
48 Gy/4 fx/isocenter T1/T2 
1-year: 
100%/100%; 
5-year: 95%/100%
T1/T2 
1-year: 93%/92%; 
2-year: 90%/71%; 
3-year: 83%/71%; 
5-year: 83%/71%
NA
Onishi et al.28  
(13 months)
35 34% 0 T1: 43%,  
T2: 57%
60 Gy/10 fxe/80–85% NA 2-year: 58% 2-year: 83%
Fukumoto et al.29 
(24 months)
22 14% 0 T1: 59%;  
T2: 41%
Based on tumor location:  
P: 60 Gy/8 fx/80%;  
C: 48 Gy/8 fx/80%
At analysis: 94% NA 1-year: 94%; 
2-year: 73%
aProportion of operable patients who refused surgery and who were included in the study.
bPrescription isodose.
cOnly medically inoperable patient subgroup.
dFollow-up period for living patients.
eTwo fractions per day.
C, center; fx, fractions; Gy, grays; med, median; n, number of patients; NA, not available; P, periphery; PTV, planning target volume; SABR, stereotactic ablative radiation therapy.
TABLE 1.  (Continued )
Study  
(Median  
Follow-up) n
Operable 
Patientsa
No Histologic 
Confirmation 
(%)
T Stage  
Distribution
SABR Dose/ 
fx/Isodoseb
Local  
Control
Overall  
Survival
Cancer- 
Specific  
Survival
TABLE 2.  Summary of SABR Efficacy Results in Medically Inoperable NSCLC Patients
Time Point No. of Studiesa na
Median of Reported Rates (Minimum–Maximum)b
Local Control Overall Survival Cancer-Specific Survival
1-year 11 506 97% (89.5–100%) 86% (74.5–93%) 93.5% (92–96%)
2-year 13 559 88% (67.9–97%) 60% (48–90%) 80.7% (62–88%)
3-year 9 689 87.9% (67.9–97.6%) 57.1% (37.4–71.7%) 82% (72.5–88%)
4-year 1 108 89% 30% 77%
5-year 1 180 NA 52% NA
aNumber of studies and patients presenting data at the indicated time point for at least one reported outcome in the table and for the entire population.
bMedian of rates reported in the included studies and not weighted according to sample size.
n: number of patients; NA: not available.
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Comparison of SABR and Surgery 
for Operable Patients
Seven retrospective studies compared SABR with sur-
gery (all techniques),47,48 lobectomy,32,48–50 lobectomy using 
video-assisted thoracoscopic surgery,51 sublobar resection,32 
and wedge resection.48,52 Most of the patients in SABR arms 
were deemed medically inoperable. Mediastinal staging in 
SABR patients, minimally by positron emission tomogra-
phy (PET) scan, was performed in all patients,47,52 only for 
a certain proportion of the patients (74%),32 or for none of 
the patients48; no information on mediastinal staging was 
reported in one study,49 and it is not clear whether a PET scan 
was performed on all the patients in two studies.50,51 In the 
studies reporting the characteristics of eligible patients before 
the matching process, the characteristics were not balanced 
between groups.47,48,50,52 The distribution of histological types 
was not different between groups in one study51 but was statis-
tically different in all other studies where histology informa-
tion was available.32,48,50,52 Propensity-score patient matching 
was used in five studies,32,47,48,50,51 patients were matched based 
on the similarity of a selection of prognostic characteristics in 
two studies,48,49 and no matching strategy was used in another.52 
In studies where both histology information was available and 
matching was done (for overall survival end point), histology 
was always used as a covariate for matching patients.32,48,51 
After the matching process, the patients’ characteristics were 
balanced in most of the studies32,47,49,51 but were still not in one 
of them,50 and balance was not tested in another.48
The results of the patient-matched or regression analy-
ses are presented in Table 6. Local control and cancer-specific 
survival were similar in the two groups in nearly all the stud-
ies. Inconsistent results were reported for overall survival: 
surgery was associated with better survival,48,50,52 survival was 
similar in both groups,32,47,49,51 and SABR was associated with 
better survival (with Cox regression analysis).47 In the four 
studies that seemed to use proper matching methods and that 
showed a balance between groups after matching, the overall 
survival results were similar in both groups.32,47,49,51
Overall, the safety profile was more favorable for SABR. 
More treatment-related deaths occurred with surgery than with 
TABLE 3.  Summary of Studies Comparing SABR with Standard EBRT
Study (Median 
Follow-up) n
SABR, Dose/fx/ 
Isodosea Std. EBRT, Dose/fx
Local Control  
(A vs. B)
Overall Survival  
(A vs. B)
Cancer-Specific 
Survival (A vs. B)
Retrospective study (Level IV evidence)
  Jeppesen et al.31 
(mean: 13.8 
months)
Total: 132; 
(A) SABR: 100 and 
(B) Std EBRT: 32
45 Gy/3 fx/95% of 
GTV or 66 Gy/3 fx/
isocenter
80 Gy/35–40 fx 1-year: 93% vs. 89%; 
5-year: 69% vs. 66%; 
p = 0.93
Med: 36.1 vs. 24.4 
months; 
1-year: 82% vs. 75%; 
5-year: 35% vs. 10%; 
p = 0.02
1-year: 94% vs. 87%; 
5-year: 61% vs. 31%; 
p = 0.09
  Shirvani et al.32 
(3.2 years)
Total: 1737; 
(A) SABR: 124 and  
(B) Std EBRT: 1613
NA NA NA HRb,c = 1.97 (95%  
CI: 1.31–2.96);  
p = 0.001
HRb,c = 1.56 (95%  
CI: 0.67–3.59);  
p = 0.30
  widder et al.33  
(13 months)
Total: 229; 
(A) SABR: 202; 
(B) Std EBRT: 27
Based on tumor 
location: 60 Gy/ 
3–8 fx/80%
3D-CRT:  
70 Gy/35 fx
2-year: 95% vs. 78%; 
HRb = 5.0 (95% CI: 
1.7–14.7); p < 0.01
2-year: 72% vs. 48%
HRb = 2.6 (95% CI: 
1.5–4.8); p < 0.01
NA
Meta-analysis (Level II evidence)
  Grutters et al.34 Number of studies: 22; 
(A) SABR: 11; 
(B) Std EBRT: 11
– – NA 2-year: 70% vs. 53%; 
p < 0.001; 
5-year: 42% vs. 19%; 
p < 0.001
2-year: 83% vs. 67%;  
p = 0.006;  
5-year: 63% vs. 43%;  
p = 0.045
aPrescription isodose.
bHazard ratio calculated for standard EBRT compared with SBRT as the reference.
cHazard ratio for propensity-matched pairs of SBRT cases and standard EBRT cases.
 CI, confidence interval; GTV, gross tumor volume; Gy, grays; HR, hazard ratio; n, number of patients; NA, not available; med, median; SABR, stereotactic ablative radiation 
therapy; Std EBRT, standard external-beam radiation therapy; 3D-CRT, three-dimensional conventionally fractionated radiotherapy.
TABLE 4.  Comparison of SABR and Standard EBRT Efficacy Results in Inoperable NSCLC Patients
Time Point
Local Control (Median) Overall Survival (Median) Cancer-Specific Survival (Median)
SABRa (%)
Std EBRTa 
(%)
SABR 
relative↑b 
(%) SABRa (%)
Std EBRTa 
(%)
SABR relative 
↑b (%) SABRa (%)
Std EBRTa 
(%)
SABR relative 
↑b (%)
1-year 97 89 9 86 75 15 94 82 15
2-year 88 59 49 60 51 18 81 66 23
3-year 88 51 73 57 33 73 82 53 55
aMedian of rates reported in the included studies and not weighted according to sample size.
bRelative increase of SABR compared with standard EBRT (%) = (SABR median rate – Std EBRT median rate) × 100/Std EBRT median rate.
SABR, stereotactic ablative radiation therapy; Std EBRT, standard external beam radiation therapy; ↑, increase.
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SABR,47,49–51 and the morbidity rates associated with surgery were 
generally higher than the toxicity rates caused by SABR.47,50,51
In a meta-analysis by Soldà et al., the overall survival 
data for SABR were similar to those for surgery (Table 6). 
The authors concluded that the survival outcome of SABR 
in the short term and medium term is equivalent to surgery 
for this patient population, regardless of comorbidity, that a 
direct comparison of the two approaches should be a priority 
and that, in the meantime, SABR should be offered to stage I 
NSCLC patients as an alternative to surgery.
Optimal Radiation Dose with SABR
Two meta-analyses have explored the optimal radia-
tion dose to be used with SABR (Level II evidence).53,54 Van 
Baardwijk et al.53 tested the correlation between the dose 
absorbed at the edge of the PTV and the local control outcome 
(15 observational studies). The doses used were normalized 
to 2-Gy equivalent doses, taking into account the total dura-
tion of treatment (EQD
2,T
). Local control could not be corre-
lated with the EQD
2,T
 when taking the whole population into 
account (r2 = 0.050; p = 0.23) or only patients treated with an 
EQD
2,T
 of 60 Gy or more (r2 = 0.042; p = 0.32).
Zhang et al.54 explored the optimal biological equivalent 
dose (BED
10
) range for the treatment of NSCLC with SABR 
(34 observational studies, Level II evidence). They calculated 
pooled estimates for local control, overall survival, and cancer-
specific survival at 1, 2, 3, and 5 years. For the analyses, four 
dose classes were established based on quartiles: low (<83.2 
Gy), medium (83.2–106 Gy), medium-to-high (106–146 Gy), 
and high (>146 Gy). For local control, all dose ranges resulted 
in rates more than 85% at 1, 2, and 3 years. For overall sur-
vival and cancer-specific survival, the highest estimates at 1 to 
3 years were generally obtained with the medium dose range, 
but the values for the medium-to-high dose range were gener-
ally not significantly lower statistically compared with those 
for the medium range. The overall survival estimates were sig-
nificantly lower at 2 and 3 years when low or high dose ranges 
were used. The data were more fragmentary at 5 years.
DISCUSSION
SABR for Medically Inoperable Patients
Although most of the prospective SABR studies in 
inoperable patients are of small size and low level of evi-
dence, their results are, on the whole, very consistent. Very 
good local control was achieved with SABR, and consider-
ing that the 3-year overall survival rates in patients with T1 
and T2 stage disease receiving no treatment are approximately 
22% and 11%, respectively,55 SABR treatment also seems to 
be associated with a survival benefit, at least when compared 
with no active treatment.
The inclusion of patients being treated without patho-
logical confirmation of malignancy in several studies may lead 
to an overestimation of the benefit of this modality.7,9,11,16,19,20 
In daily practice, a biopsy can constitute a risk for certain 
patients. Predictive criteria for malignancy may be used (e.g., 
morphological appearance, tumor progression with time, and 
avidity to 18F-FDG on PET scan). However, some lesions 
TABLE 5.  Summary of Studies Evaluating SABR in Operable NSCLC Patients
Study
Median Follow- 
up n T stage Distribution SABR Dose/fx/Isodosea Local Control Overall Survival
Cancer-Specific 
Survival
Prospective studies (Level II evidence)
  Shibamoto 
et al.8
36 monthsb 60 T1: 71%, T2: 29%b Based on tumor size:  
44–52 Gy/4 fx/isocenter
3-year: 86% 3-year: 74% 3-year: 82%
  Onishi et al.28 13 monthsb 12 T1: 43%; T2: 57%b 60 Gy/10 fxc/80–85% NA 2-year: 83% NA
Retrospective studies (Level III evidence)
  Grills et al.41 1.3 yearsb 56 T1: 63%, T2: 33%, 
T3: 2%b
Med: 54 Gy/3 fx/NA NA 2-year: 78% NA
  Lagerwaard  
et al.40
31.5 monthsb 177 T1: 60%, T2: 40% Based on tumor size and 
location: 60 Gy/3–8 fx/80%
1-year: 98%,
3-year: 93%
Med: 61.5 months;  
1-year: 94.7%;  
3-year: 84.7%
NA
  Takeda et al.42 21 monthsb 38 T1: 58%, T2: 37%,  
T3: 1.1%, T4: 3.5%b
Based on the presence of 
adjacent critical structure: 
40–50 Gy/5 fx/80%
NA 3-year: 86% NA
  Onishi et al.43 55 months 87 T1: 74%; T2: 26% Typical dose and fx:  
75 Gy/10 fx/85–95% or 48 Gy/ 
4 fx/85–95%
5-year: 86.7% 5-year: 69.5% 5-year: 76.1%
  Inoue et al.45 14 monthsb 43 T1: 81%; T2: 19%b 30–70 Gy/2–10 fx/isocenter NA 3-year: 88.4%;  
5-year: 88.4%
NA
  Hiraoka and 
Nagata44
NA 241b T1: 63%; T2: 37%b BED
10
: 57–180 Gy  
(med: 108 Gy)
NA BED
10
 > 100 Gy;  
3-year: 91%
NA
  Uematsu et al.46 36 monthsb 29 T1: 48%; T2: 52%b 50–60 Gy/5–10 fx/NA NA 3-year: 86% NA
aPrescription isodose.
bOperable patients constituted a subgroup. The data presented are for the global population.
cTwo fractions per day.
BED
10
: biological equivalent dose (α/β = 10 Gy); fx: fractions; Gy: grays; n: number of patients; NA: not available; SABR: stereotactic ablative radiation therapy.
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TABLE 6.  Summary of Studies Comparing SABR with Surgery
Study (Median 
Follow-up) n
SABR Dose/fx/ 
Isodosea Surgery Local Control (A vs. B)b
Overall Survival  
(A vs. B [vs. C])b
Cancer-Specific 
Survival  
(A vs. B [vs. C])b
Retrospective studies (Level IV evidence)
Varlotto et al.48  
(A, B, and C: 
18.8, 31, and  
35 months)
Total: 317; 
(A) SABR: 137,  
(B) lobectomy: 132,  
(C) Sublobar  
resection: 48
Mean: 60 Gy/ 
3 fx/NA
Lobectomy and 
sublobar resection  
(all wedge 
resections)
NA, Locoregional control, 
A vs. B; 
2-year: 87.8% vs. 88.7%; 
3-year: 87.8% vs. 81.2%; 
5-year: 87.8% vs. 81.2%;
p = 0.382. 
A vs. C:  
2-year: 95.2% vs. 94.1%;  
3-year: 78% vs. 86.3%; 
5-year: 78% vs. 86.3%;  
p = 0.468
A vs. B:  
2-year: 66.2% vs. 75%; 
3-year: 40.9% vs. 69.2%; 
5-year: 33.7% vs. 69.2%;  
p = 0.004. 
A vs. C:  
2-year: 50.8% vs. 94.1%; 
3-year: 42.3% vs. 86.3%; 
5-year: 31.7% vs. 86.3%;  
p = 0.003.  
Multivariate analysis 
(+propensity score).  
A vs. B and C: p = 0.238
NA
Robinson et al.50 
(A and B: 
51.3 and 50.3 
months)
Total: 338;  
(A) SABR: 78 and  
(B) Lobar resection: 
260
Med: 54 Gy/ 
3 fx/60–90%
Lobectomy  
(n = 237),  
bilobectomy or 
pneumonectomy 
through open 
thoracotomy  
(n = 224) or  
VATS (n = 36)
4-year: 93.5% vs. 98.5%;  
p = 0.222
4-yearc: 29.3% vs. 57.9%; 
p = 0.0007
4-yearc:  
74.7% vs. 77.3%;  
p = 0.898
Verstegen et al.51 
(A and B: 30 
and 16 months)
Total: 128;  
(A) SABR: 64 and  
(B) lobectomy: 64
Risk-adapted: 
54–60 Gy/ 
3–12 fx/NA
VATS lobectomy Locoregional control: 
1-year: 96.8% vs. 86.9%; 
3-year: 93.8% vs. 82.6%; 
HR = 3.68 (95% CI: 
1.09–12.5); p = 0.04
1-year: 91.8% vs. 90.8%; 
3-year: 79.6% vs. 76.9%; 
HR = 1.09 (95% CI: 
0.50–2.36); 
p = 0.83
NA
Shirvani et al.32 
(3.2 years)
Total: 7932;  
((A) SABR: 124,  
(B) lobectomy: 6531, 
(C) Sublobar resection: 
1277
NA NA NA A vs. B:  
HRd = 0.71 (95% CI: 
0.45–1.12);  
p = 0.14. A vs. C:  
HRd = 0.82 (95% CI: 
0.53–1.27);  
p = 0.38
A vs. B:  
HRd = 1.00 (95%  
CI: 0.40–2.52);  
p = 0.99. 
A vs. C: 
HRd = 2.14 (95%  
CI: 0.87–5.26);  
p = 0.10
Palma et al.49  
(43 months)
Total: 120;  
(A) SABR: 60 and  
(B) lobectomy: 60
Majority  
(n = 51):
60 Gy/3–8 fx/ 
NA
Lobectomy  
(n = 49), sublobar 
excision (n = 9), 
pneumonectomy  
(n = 2)
NA 1-year: 87% vs. 75%; 
3-year: 42% vs. 60%;  
p = 0.22
NA
Grills et al.52  
(2.5 years)
Total: 124;  
(A) SABR: 55 and  
(B) wedge resection: 69
Depending on 
tumor stage (T1 
or T2: 48 or 60 
Gy/4–5 fx/80%
wedge resection 
through open 
thoracotomy  
(n = 33) or  
VATS (n = 36)
Unadjusted analysis:  
30 months: 4% vs. 20%;  
p = 0.07
Unadjusted analysis: 30 
months: 72% vs. 87%;  
p = 0.01
Unadjusted 
analysis:  
30 months:  
93% vs. 94%;  
p = 0.53
Crabtree et al.47  
(A and B: 19 
and 31 months)
Total: 538;  
(A) SABR: 76 and  
(B) Surgery: 462
54 Gy/3 fx/ 
80–85%
At the treating 
surgeon’s  
discretion
HRe = 0.47 (95% CI: 
0.16–1.41); p = 0.182; 
Propensity-matched 
comparison: p = 0.9
HRe = 0.66 (95% CI: 
0.43–0.92); p = 0.020
Propensity matched 
comparison: p = 0.27
HRe = 0.77 (95% 
CI: 0.40–1.48); 
p = 0.448; 
Propensity matched 
comparison:  
p = 0.7
Meta-analysis (Level II evidence)
  Soldà et al.65 Total: 2038–3171; (A) 
SABR and (B) Surgery
Variable Variable 91% vs. NA 70% vs. 68% NA
aPrescription isodose.
bResults of matched-pair comparison only.
cPropensity scores calculated with prognostic factors for distant control (not valid for the overall survival end point).
dSABR was used as the reference in Cox regression.
eSurgery was used as the reference in Cox regression.
 CI: confidence interval; fx: fractions; Gy: grays; HR: hazard ratio; med: median; n: number of patients; NA: not available; SABR: stereotactic ablative radiation therapy; VATS: 
video-assisted thoracoscopic surgery.
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could still be benign and treated unnecessarily or have a lep-
idic-predominant histology and therefore be associated with a 
better outcome. In about one-fourth of the studies, the benefits 
may also have been underestimated because thoracic lymph 
node staging was not performed systematically.8,11,19–21,29
Regarding toxicity, overall studies have shown SABR to 
be safe. Radiation pneumonitis was the most often observed 
toxicity, but in most cases it was of grade 1 or 2. However, in a 
few studies, toxicity rates of grade 3 or more were higher than 
the average rates, which raises some safety concerns.10,13,18,20,24 
This could be explained by the use of higher doses (60 Gy or 
more in 3 or 4 fractions)10,13,18 without a substantial dose and/or 
fractionation adjustment for central tumors10,18 or without hav-
ing been able to comply with normal-tissue dose constraints in 
a large proportion of the patients (27%).13 A dose of 60 Gy in 
three fractions has also been used in other studies, with more 
favorable toxicity profiles.7,9,12,15 However, in these studies, the 
doses were adjusted to the toxicity risk. Higher toxicity rates 
could also be because of, at least in part, the severe baseline 
respiratory comorbidities in a certain proportion of the patients 
rather than being due to the treatment itself.20,24 As for quality 
of life, it does not seem to be reduced by SABR, and SABR 
actually appears to improve the emotional functioning score.7,12
The three retrospective studies comparing SABR with 
standard EBRT were of low level of evidence. The main meth-
odological concerns regarding these studies included unbal-
anced groups,31,33 different imaging methods used during 
follow-ups between the groups, short follow-up, and a gap of 
at least 10 years between when the two groups were treated.33 
All of the studies, including the meta-analysis of cohort stud-
ies, showed a significant benefit in favor of SABR.
Although the evidence seems to favor SABR over standard 
EBRT in terms of overall survival and cancer-specific survival, 
there remains some uncertainty regarding these results because 
no direct comparison in RCTs has been performed. In our indi-
rect comparison of SABR with standard EBRT, the results were 
in favor of SABR, with relative improvement in local control, 
overall survival, and cancer-specific survival of 73%, 73%, and 
55%, respectively. The magnitude of these differences appears 
to be too large to be completely explained by the bias that may 
underlie the indirect nature of this comparison. Three RCTs, 
highly Conformal Hypofractionated Image guided Stereotactic 
radiotherapy for inoperable Early stage non-small-cell Lung 
cancer (CHISEL), Stereotactic Precision AND Conventional 
Radiotherapy Evaluation (SPACE), and StereoTactic body 
Radiotherapy in medically inoperable non-small-cell LUng can-
cer patients (LUSTRE), presently registered on ClinicalTrials.
gov (NCT01014130, NCT01920789, and NCT01968941), may 
provide more definitive evidence regarding the comparative effi-
cacy and safety of these treatments, but as SABR is increasingly 
being recommended by organizations involved in cancer care,56–
61 recruitment might be difficult.
Given the results of prospective studies of SABR, the 
comparative retrospective studies, the meta-analysis, and the 
substantial differences in results favoring SABR in our indi-
rect comparison, the CEPO considers SABR to be superior to 
standard EBRT, with a reasonable level of confidence, for the 
treatment of inoperable early-stage NSCLC patients.
SABR for Operable Patients
Most results in operable patients come from studies 
involving a large majority of inoperable patients.8,28,41,42,44–46 
Only two studies focused solely on operable patients.40,43 
SABR achieved very good local control, which was similar to 
what was reported in inoperable patients. The overall survival 
data showed very similar figures from 2 to 5 years (plateau), 
suggesting that long-term survival can be achieved with this 
treatment.8,28,40–46 Results from the ongoing phase II prospec-
tive trial JCOG-0403, focusing on SABR for the treatment of 
operable patients with T1 stage NSCLC (n = 64), were in the 
same order of magnitude, with 3-year local control and over-
all survival rates of 86% and 76%, respectively.62
To date, high level of evidence data comparing SABR 
with surgery is lacking. Matching methods were used to 
compare patients with a similar prognosis but, because the 
prognosis of patients in cohorts treated with SABR and sur-
gery overlaps only partially, only a certain proportion of 
patients could be matched, likely leaving out the surgically 
treated patients with the best prognosis. The listed stud-
ies were flawed with many methodological concerns, nota-
bly lack of balance between groups after matching,48,50 not 
enough matchable patients to perform the planned analyses,50 
no matching at all,52 a likely lack of power with all studies 
(SABR: n = 55–137), and a short follow-up time.47,48,51
SABR was compared with several surgical interven-
tions, from lobectomy to wedge resection. The results between 
the studies were not consistent in terms of local control and 
overall survival, and no difference in cancer-specific survival 
was demonstrated. Variability in local control may be because 
of the different definitions used depending on the treatment. 
In fact, whereas recurrence is said to be local when occurring 
in the PTV after treatment with radiotherapy, local recurrence 
is often defined as a failure localized up to the whole hemi-
thorax after surgery, which could also include distant failure 
under the current staging system. The risk of treatment-related 
death and the complication/toxicity profiles generally favored 
SABR. This was particularly true in high-surgical-risk patients 
and in elderly patients (≥80 years of age).47,49
Overall, there is at this time no firm evidence support-
ing the use of SABR as an alternative to surgery. There are 
presently two phase II (NCT01622621 and NCT01753414) 
and three phase III (NCT01336894, NCT00687986 and 
NCT00840749) RCTs registered in the ClinicalTrial.gov 
database, but all three phase III studies were stopped prema-
turely because of poor recruitment.
Optimal Radiation Dose with SABR
As shown by Zhang et al., the best results for SABR are 
achieved with the BED
10
 ranges of 83.2 to 106 Gy and 106 to 
146 Gy. However, it is important to note that for the BED
10
 range 
of 83.2 to 106 Gy, no study used a BED
10
 below 94 Gy (median: 
100 Gy). Thus, these results are in line with those of an earlier 
study proposing that the optimal dose is 100 Gy or higher.63
In conclusion, in inoperable patients with early-stage 
NSCLC, SABR achieved very good local control and cancer-
specific survival with acceptable toxicity. The data available to 
date indicate with a reasonable level of confidence that better 
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oncological results are achieved with SABR than with standard 
EBRT. The optimal BED
10
 with SABR appears to be at least 100 
Gy, and some evidence suggests that doses higher than 150 Gy 
could be detrimental. Despite SABR’s favorable toxicity profile, 
caution should be exercised for tumors that are central or of large 
volume (large PTV), and patients with severe pulmonary comor-
bidity. In such cases, a dose and/or fractionation adjustment based 
on the risk should be considered. In operable patients, the level 
of evidence of the data comparing SABR with surgery is too low 
to draw any conclusions regarding the role of SABR as an alter-
native to surgery. Consequently, lobectomy (or pneumonectomy, 
when more appropriate) is still considered the standard treat-
ment for operable patients. SABR should not be offered to these 
patients, unless they refuse surgery. As opposed to SABR, surgery 
allows en bloc resection of the primary tumor, the removal of the 
draining nodes, definitive assessment of the tumor histology, and 
mediastinal staging. For patients who could only tolerate a sub-
lobar resection, no good-quality data are available to definitively 
guide the choice toward surgery or SABR. This choice must be 
discussed within tumor boards, taking into account the severity 
of the patient’s comorbidities, the advantages and disadvantages 
of the treatments, and the local expertise. Finally, because a high 
proportion of inoperable patients die from their comorbidities 
rather than from their lung cancer, radiotherapy (SABR or stan-
dard EBRT) should not be offered to patients with a very limited 
life expectancy, as assessed by a multidisciplinary team, to avoid 
unnecessary treatment-related risks.
Recommendations
Considering the evidence available to date, the CEPO 
recommends the following:
1.  For medically operable patients with stage T1-2N0M0 
NSCLC, surgery remains the standard treatment because 
comparative data regarding the efficacy of SABR and sur-
gery are currently insufficient for SABR to be considered 
an equivalent alternative to surgery for these patients;
2.  For medically inoperable patients with stage T1-2N0M0 
NSCLC or medically operable patients who refuse sur-
gery, SABR should be preferred to standard EBRT (grade 
B recommendation);
3. The biological equivalent dose (BED
10
) used for SABR 
treatment should be at least 100 Gy (grade B recommen-
dation);
4.  For patients with a central tumor, a large-volume tu-
mor (large PTV), or severe pulmonary comorbidity, 
a risk-adapted schedule should be used (dose reduc-
tion or increase in the number of fractions; grade B 
 recommendation);
5.  The choice of using SABR to treat NSCLC should be 
discussed within tumor boards; treatment with SABR (or 
with standard EBRT) should not be considered for patients 
whose life expectancy is very limited because of comor-
bidities (grade D recommendation).
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